Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1951 1
1952 3
1953 5
1954 3
1955 3
1956 8
1957 18
1958 13
1959 13
1960 10
1961 16
1962 13
1963 16
1964 9
1965 17
1966 14
1967 10
1968 7
1969 10
1970 19
1971 12
1972 18
1973 25
1974 25
1975 21
1976 21
1977 22
1978 25
1979 17
1980 26
1981 19
1982 27
1983 24
1984 28
1985 29
1986 38
1987 49
1988 52
1989 47
1990 35
1991 46
1992 46
1993 57
1994 69
1995 83
1996 88
1997 86
1998 104
1999 97
2000 117
2001 132
2002 176
2003 152
2004 208
2005 268
2006 262
2007 270
2008 339
2009 342
2010 415
2011 482
2012 493
2013 565
2014 604
2015 664
2016 682
2017 711
2018 780
2019 877
2020 1022
2021 1145
2022 1323
2023 1246
2024 1262
2025 1444
2026 921

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16,548 results

Results by year

Filters applied: . Clear all
Page 1
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.
Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, Punekar SR, Barve M, Pelster M, Herzberg B, Azad NS, Hecht JR, Ou SHI, Lin T, Kar S, Tao L, Vora R, Hegde A, Aung K, Hong DS; RMC-6236-001 Investigators. Wolpin BM, et al. Among authors: lin t. N Engl J Med. 2026 May 7;394(18):1790-1802. doi: 10.1056/NEJMoa2505783. N Engl J Med. 2026. PMID: 42090791 Clinical Trial.
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.
Wang ES, Erba HP, Zeidan AM, Roboz GJ, Altman JK, Advani AS, Lin TL, Strickland SA, Juckett MB, Pratz KW, Mangan JK, McMahon CM, Alsfeld LC, Balasubramanian SK, Guru Murthy GS, Rotta M, Palmisiano N, McCloskey J, Saliba AN, Khawandanah M, Madanat YF, Naqvi K, Qasrawi AH, Schiller GJ, Badar T, Gojo I, Yaghmour G, Osman D, Zhang H, Tian Y, Soifer HS, Riches M, Corum D, Leoni M, Fathi AT, Issa GC. Wang ES, et al. Among authors: lin tl. Blood. 2026 Jun 2:blood.2026034043. doi: 10.1182/blood.2026034043. Online ahead of print. Blood. 2026. PMID: 42227701 Free article.
Complicated pericardial effusion.
Lin TY, Chien YT, Lin YT, Lin PY. Lin TY, et al. Int J Cardiovasc Imaging. 2026 Apr 27. doi: 10.1007/s10554-026-03721-w. Online ahead of print. Int J Cardiovasc Imaging. 2026. PMID: 42036618
STK38/L promote tissue growth and cancer by inhibiting the Hippo pathway.
An J, Huang Z, Kizhedathu A, Lan T, Lin T, Joo H, Thilakaratne EM, Liu Y, Xu YY, Yang B, Lara-Gonzalez P, Warrior R, Luo R, Wang W. An J, et al. Among authors: lin t. Genes Dev. 2026 Jul 1;40(13-14):1080-1098. doi: 10.1101/gad.353309.125. Genes Dev. 2026. PMID: 42128666
An intrinsic cytoskeletal oscillator establishes neuronal polarity.
Lin TC, Coles CH, Alfadil E, Fäßler F, Husch A, Dupraz S, Pietralla T, Narita A, Schelski M, Flynn KC, Stern S, Möhl C, Hilton BJ, Vauti F, Arnold HH, Schur FKM, Bradke F. Lin TC, et al. Nature. 2026 Jul 8. doi: 10.1038/s41586-026-10755-6. Online ahead of print. Nature. 2026. PMID: 42420447
Acute and Subacute Cough.
Hoag E, Patel K, Farris S, Lin TF. Hoag E, et al. Among authors: lin tf. Otolaryngol Clin North Am. 2026 Aug;59(4):731-745. doi: 10.1016/j.otc.2026.03.012. Epub 2026 May 27. Otolaryngol Clin North Am. 2026. PMID: 42203564 Review.
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Lachowiez CA, Zeidner JF, Othman J, Kaempf A, Yun S, Heiblig M, Heuser M, Shahswar R, Madero Marroquin R, Cannova JM, Žučenka A, Marvin-Peek J, Senapati J, Abaza Y, Swaroop A, Zacheo I, Monaco F, Belhabri A, Tauveron-Jalenques U, Tavernier E, Carré M, Aspas Requena G, Cook RJ, Traer E, Saultz JN, O'Nions J, Basheer F, Laurie J, Handa S, Stein EM, Baer MR, Olin R, Blum W, Schiller G, Lin T, Curran E, Yocum A, Madarang E, Daver N, Kadia TM, Marconi G, Madanat Y, Dillon R, DiNardo CD, Swords R, Arango Ossa JE, Watts J, Loghavi S, Pollyea DA, Bernard E; PRISM-AML Investigators. Lachowiez CA, et al. Among authors: lin t. J Clin Oncol. 2026 Jul 2:JCO2600347. doi: 10.1200/JCO-26-00347. Online ahead of print. J Clin Oncol. 2026. PMID: 42391582
CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.
Juric D, Islam KN, Gkotinakou IM, Zheng A, Lee H, Saxena S, Kreuzer J, Morris R, McGrath CG, Sakhtemani R, Chevalier NJ, Kehlmann AM, Stavridi AM, Tajmir S, Stanzione M, Zaniewski EF, Mahan S, Hodel K, Meyers M, Sampath S, Schmedt C, Sampath SC, Lin TT, Liu F, VanArsdale T, Isakoff SJ, Comander A, Kim JS, Wander SA, Knudsen ES, Witkiewicz AK, Zou L, Hata AN, Lawrence MS, Haas W, Varkaris A, Sanidas I. Juric D, et al. Among authors: lin tt. Cancer Res. 2026 Jul 2. doi: 10.1158/0008-5472.CAN-25-1859. Online ahead of print. Cancer Res. 2026. PMID: 42391342
16,548 results
You have reached the last available page of results. Please see the User Guide for more information.